Growth hormone (GH) exerts its effects on target tissues either directly or via the production 66 of insulin-like growth factor 1 (IGF-I). Accurate measurement of IGF-I in serum is crucial for 67 diagnosis and management of disorders affecting the somatotropic axis, particularly GH 68 excess (acromegaly) and GH deficiency (GHD). However, even if manufacturers follow the 69 recommendations of the Consensus Group on the Standardization and Evaluation of GH and 70 IGF-I Assays (1), the different commercial IGF-I assay kits can give very different results for 71 the same sample, with up to a 2.5-fold difference between the lowest and highest values (2) . 72
This inter-method variability is generally explained by calibration against different IGF-I 73 reference preparations (3), and differences in the efficiency of methods used to remove IGF-74 binding proteins (IGFBPs) (4). In theory, this should not be a problem in clinical practice, as 75
kits that give higher values should have higher normal limits, and patients should thus be 76 consistently classified. 77
However, it is very difficult to establish reference values for IGF-I. Indeed, serum IGF-I 78 concentrations increase with children's age and pubertal stage, while they fall with age in 79 adults (5). Furthermore, the distribution of IGF-I values in an apparently healthy population is 80 non Gaussian, and this necessitates complex mathematical transformation to obtain reference 81 intervals for each age group. For this reason, it is essential to generate reference values after 82 stratifying a large healthy population into age groups. Another problem is that IGF-I 83 concentrations are influenced by many factors other than GH concentrations, including 84 nutritional status and BMI, use of hormone replacement therapy by post-menopausal women, 85 depending on the administration route (6-8), kidney and liver function, and diabetic status (9) . 86
Reference IGF-I values may therefore be influenced by the inclusion criteria used to select the 87 reference population sample. This could have important implications for diagnosis and 88 therapeutic decision-making, as a given patient could be classified as having a normal IGF-I 89 concentration with one method but an abnormal value with another method. Several studies 90 suggest that the main reason for inter-laboratory variability in patient classification is the use 91 of different populations to establish reference values for the different IGF-I assays (2, 10, 11) . 92
It is currently difficult to monitor an individual patient with different IGF-I assays, even if the 93 results are all expressed in the same units (ng/ml). It is thus recommended to establish 94 specific reference ranges for each assay, and to apply common, well-defined inclusion criteria 95 to the reference population (1). It is also recommended, for the comparison of values obtained 96 with different assays in the same patient, to express each IGF-I result as an SD score (SDS) 97 with reference to the normative data for the assay in question, after appropriate transformation 98 for data non normality. We reasoned that the best way to overcome this variability would be 99 to apply all the commercial kits used in clinical laboratories to a battery of samples from the 100 same well-defined reference population, and to use the same mathematical transformation to 101 calculate reference ranges from the raw data. 102
The aim of this study was thus to establish normative data for six commercial IGF-1 assays in 103 a large random sample of healthy subjects from the French general population representing all 104 adult age groups (about 100 subjects per decade), as recommended by the Consensus Group 105 on the Standardization and Evaluation of GH and IGF-I assays (1). Serum samples from the 106 reference population were tested with six commercial assay kits available in France at the 107 time of this study, after careful exclusion of subjects with medical conditions or medications 108 that might affect their IGF-I concentration. The data were analyzed to obtain the range (2.5 to 109 97.5 percentiles) in mass units. The standard deviation scores were used to compare the six 110 assays. 111 112
Subjects and Methods 113

IGF-I assay characteristics 114
Six immunoassays (iSYS, LIAISON XL, IMMULITE, IGFI RIACT, Mediagnost ELISA, and 115
Mediagnost RIA) were used to measure the IGF-I concentration in each healthy subject. The 116 main characteristics of the assays, and the mathematical models used to determine normative 117 data, where relevant (12) (13) (14) , are shown in Table 1 . 118 119
Healthy subjects 120
The subjects were part of a large cohort of French healthy adults (VARIETE were then performed, and 80 mL of blood (50 mL without anticoagulant and 30 mL in 136 EDTA-containing tubes) was sampled and promptly centrifuged (2000 g, 4°C) . Serum and 137 plasma were aliquoted, frozen, and stored at -80°C until hormone measurements. 138
All healthy subjects gave their written informed consent to participate in the study, which was 139 approved by the Paris-Sud Ethics committee before the beginning of the study. 140 141
Statistical methods 142
The distribution of IGF-1 values obtained with each assay was skewed, and was thus first 143 normalized by means of sex-and age-specific Box-Cox power transformation. Student's t test 144
and Levene's test were then used to assess equality of means and homogeneity of variances 145 between men and women in each age group. As men and women had significantly different 146 IGF-1 levels, centile curves were constructed separately for each sex. 147
Age-and sex-specific centile curves were constructed for each assay by using the LMS 148 method (12) implemented in the GAMLSS software package version 4.3-1 (15) of R software 149 were also computed for each age and sex class. SD scores (SDS) were calculated as z = 155
[(IGF-1 / M) L -1]/(L × S), where IGF-I is the raw value given by the assay (in ng/mL). For 156 each technique, SDS were categorized as low, normal or high according to their positions 157 relative to both the 2.5 th and 97.5 th percentiles. 158
Once the L, M and S parameters for each category of age and sex had been obtained, the 159 lower and upper reference interval limits were determined for each assay by fixing z at -1.96 160 and 1.96, respectively, and then mathematically back-transforming the SD score formula. 161
Pairwise concordance between assays was assessed with scatter plots and Bland-Altman plots 162 for both IGF-1 raw values and SDS values, as well as with the percentage of observed 163 agreement (total number of agreements divided by the total number of patients tested with 164 both assays) and the linearly weighted Kappa coefficient for categorized 17) . 165
An overall kappa coefficient (16) 
1-Description of the population 174
Nine hundred seventy-two subjects were initially recruited, of whom 52 were excluded 175 because of abnormal values in the standard laboratory screening tests. A further 9 subjects 176
were excluded because of missing information on pregnancy status or viral serology. The 177 study population thus consisted of 911 subjects (470 males), comprising respectively 101, 178 118, 99, 98, 103, 102, 108, 97 and 85 subjects in the 18-20, 21-23, 24-26, 27-29, 30-39, 40-179 49, 50-59, 60-69, 70-89 year age groups. Mean BMI was 23.0 ± 2.4 kg/m 2 . 180 181
2-IGF-I reference intervals obtained with the six assays 182
The IGF-I reference intervals (2.5 th -97.5 th percentiles) obtained with the six immunoassays 183 are shown in Table 2 according to age and sex. Supplemental Figure 1 shows individual 184 points and fitted percentiles (2.5%, 50% and 97.5%) for males and females in each IGF-I 185
assay. 186
A calculator available online (http://ticemed_sa.upmc.fr/sd_score/) or by using Apps (IGF-I 187 SD_score) downloadable for Android from Google Play and for iOS from Apple Store (free of charge) allows to obtain individual IGF-I SDS after entering the name of the assay, the 189 individual IGF-I value obtained with the assay, and the sex and age of the individual. 190
The six reference intervals for males and females are plotted on the same graph in Figure 1 . 191 While the lower limits of the reference intervals (2.5 th percentiles) were similar, the upper 192 limits (97.5 th percentiles) varied markedly from one assay to another. 193
3-Comparison of IGF-I levels given by the six assays 194
The results obtained with each IGF-I assay were compared with those obtained with each of Whatever the assay, IGF-I concentrations were generally higher in women than in men until 198 the age of 59 years (this was significant for the age ranges 18-20 and 24-26 years). From the 199 age of 60 years, IGF-I levels were slightly higher in men than in women, although the gender 200 difference was smaller than in the younger age groups and was only significant for Immulite, 201
Mediagnost Elisa and Mediagnost RIA. Pairwise assay concordances assessed with the weighted Kappa coefficient for categorized 208 IGF-1 SDS are shown in Table 3 . The concordances were moderate to good (0.38 to 0.70), 209 although the percentages of observed agreement were quite high (94% to 97%). 210
Overall agreement was moderate as overall Kappa coefficient was 0.55. Both in men and 211 women, global inter-assay comparison showed significant differences (p<0.0001) on raw 212 values but not on SDS values (p=0.26 and p=0.36, respectively). 213 Table 4 shows pairwise concordances between the reference intervals provided by the 214 manufacturer and those obtained in the VARIETE cohort, as assessed by the Kappa 215 coefficient and the percentage agreement for each IGF-I assay. The concordances and 216 percentages of observed agreement were generally poor. 217 218
Discussion 219
We report reference intervals for IGF-I concentrations obtained with six 220 immunoassays in the same population of nearly 900 French healthy subjects aged from 18 to 221 90 years, in keeping with the 2011 recommendations of the Consensus Group on the 222
Standardization and Evaluation of GH and IGF-I assays (1). The population comprised about 223 100 subjects per age decade, and specific reference intervals were calculated for each sex and 224 age group. The reference intervals varied from one assay to another: the lower limits of the 225 normal range (2.5 th percentile) were quite similar with the six methods, but the upper limits 226 (97.5 th percentile) varied widely from one assay to another, in both men and women ( Figure  227 1). Although the pre-analytic conditions were the same for the six kits, and although four of 228 the six kits were calibrated against the international reference standard 02/254, concordance 229 between the assays, as assessed with Bland-Altman plots and the Kappa coefficient, remained 230 quite variable, not only for raw IGF-I values but also for IGF-I SDS. This latter result was 231 somewhat surprising, as we expected that, by using the same healthy population, we would 232 obtain similar SDS. 233
In table 2, which shows the reference ranges for each assay, we have deliberately 234 omitted the mean and SD calculated for each age category from the raw values, in order to 235 avoid erroneous calculations of SDS. Indeed, the Box-Cox power transformation, which is 236 necessary because of the non Gaussian distribution in each age category, uses parameters (L 237 for skewness, M for median and S for the coefficient of variation) that are specific to each 238 assay and also to each age group and gender. We thus propose an online calculator available 239 either following this link (http://ticemed_sa.upmc.fr/sd_score/) or by using Apps (IGF-I 240 SD_score) downloadable for Android from Google Play and for iOS from Apple Store (free 241 of charge) which allows to determine SDS as a function of the assay method, the measured 242 IGF-I value, gender, and age. L, M and S parameters are also provided in Supplemental Table  243 1. 244
Reliable reference intervals are crucial for interpreting IGF-I values in adults with 245 acromegaly (for diagnosis and assessment of disease control during treatment), and also for 246 diagnosing GH deficiency and monitoring GH therapy (4, 5, 19, 20) . Reference intervals 247 obtained with the IGF-I Nichols Advantage assay in a very large population of healthy 248 subjects (21) were once widely used for research and clinical practice. However, market 249 withdrawal of this assay, together with the availability of numerous automated methods with 250 considerable heterogeneity, led to calls for improved comparability and reliable normative 251 data. One important first step was the creation of the recombinant international IGF-I standard 252 preparation 02/254 (22) . A consensus conference held in 2011 proposed that all assays be 253 calibrated against this standard, and advocated precise pre-analytical and analytical conditions 254
(1). Another recommendation was to establish normative data based on a random selection of 255 individuals from the background population, with representation of all age groups (1). The 256 first normative data for the iSYS IGF-I assay, based on these recommendations and on a very 257 large healthy population, were published by Bidlingmaier et al (23) . We now propose 258 reference intervals for six IGF-I assays also based on a large population of healthy subjects. It 259 should be noted that we used very stringent inclusion criteria. Indeed, despite the large sample 260 size (almost one thousand healthy subjects, with about 100 subjects per age group), all the 261 subjects had a clinical examination, including assessment of gonadal status, and also a careful 262 medical history taking that included ongoing medications. Furthermore, all the subjects had an extensive standard biological work-up in order to exclude those with disorders capable of 264 influencing IGF-I levels or their measurement. These very strict inclusion and exclusion 265 criteria allow to define a population as "healthy" as possible; however this implies that these 266 normative data will not be strictly applicable to patients with BMI > 28 kg/m 2 or to patients 267 with oral treatment with estrogens. 268
As expected, IGF-I concentrations fell gradually with age in both sexes, irrespective of the 269 assay. Contrary to previous reports (21,23), we found a gender difference, with higher IGF-I 270 levels in women than in men, whatever the assay, until the 5 th decade. After 50 years of age, 271 however, IGF-I levels were higher in men than in women, as reported elsewhere (21, 23) . We 272 therefore propose separate normative data for men and women. One possible explanation for 273 the discrepancy between this work and previous reports is that we excluded all subjects 274
receiving steroid hormones such as estrogens. Indeed, oral estrogen is known to lower IGF-1 275 levels (6-8). In premenopausal women, for example, contraceptive pills containing ethinyl 276 estradiol reduce IGF-I levels by up to an average of 30% (24-27). Another explanation might 277 be the size of our population. Indeed, in their study involving a larger number of subjects 278 (15,000), Bidlingmaier et al. did not find differences in terms of gender differences (23). 279
Inter-assay differences in IGF-I reference intervals are a well-known issue that has 280 previously been underlined by one of us (28, 29) and by many other researchers 281 (2, 11, 23, 30, 31) . In this study, as expected, the largest inter-centile intervals (and highest 282 values) were obtained with the two assays calibrated with the old standard IRP 87/518 283 (IMMULITE and IGFI RIACT). Moreover, the three automated methods (iSYS, Liaison XL 284 and IMMULITE), which should theoretically be the most reproducible, did not yield narrower 285 reference intervals. For example, the iSYS automated method and the Mediagnost RIA 286 manual method gave very similar intervals for both men and women in all age groups. Thus, 287 the main source of variation does not appear to be analytical reproducibility. Using the same 288 iSYS method and a similar transformation for normalizing data and constructing specific 289 centile curves in the LMS method, our 2.5 th and 97.5 th percentiles were generally slightly 290 higher and our intervals generally narrower than those reported by Bidlingmaier et al. (23) . 291
Although inter-laboratory variability may play a role in these discrepancies, they are likely 292 due mainly to differences in the population samples (our population was smaller, and the 293 inclusion criteria were different). Another issue raised by our study is the poor concordance 294 between our reference intervals and those proposed by the assay manufacturers. Once again 295 this might be related to the use of different background populations: indeed, those used by 296 manufacturers may not fulfill all the criteria recommended by the consensus group in 2011, 297
particularly with respect to their size, the definition of healthy subjects, and the use of 298 hormonal contraceptives (Supplemental Material) . 299
Likewise, one obvious explanation for the discordance between assays is the use of different 300 populations to establish reference intervals. This is why we used the same reference 301 population for all the kits. However, although the six assays showed comparable analytical 302 performance in terms of their reproducibility and detection limits (Table 1) , and despite the 303 fact that they use the same non-competitive "sandwich" format and similar methods to avoid 304 IGFBP interference (IGF-II addition), the reference values obtained in our well-controlled 305 adult population differed strikingly from one assay to another. Two of the six assays 306 (IMMULITE and IGF-I RIACT) are still calibrated against the old IRR 87/518 standard, 307
whereas the other four are calibrated against the new IRR 02/254 standard, as currently 308 recommended (1). As expected, the former two assays gave the highest upper reference range 309 for both sexes until the age of 50 (Table 2, Figure 1 ). However, the reference ranges of two 310 differently calibrated kits may be either similar (e.g. LIAISON XL and IGFI RIACT in men), 311 or significantly different (e.g. iSYS lower than IMMULITE) (Table 2) . Likewise, reference 312 ranges determined with kits calibrated against the same reference preparation may also be 313 significantly different, even for kits from the same manufacturer (e.g. the RIA and ELISA kits 314 from Mediagnost). It therefore seems likely that the observed differences are related to other 315 analytical factors, such as the efficiency of IGFBP interference removal and the specificity 316 and/or affinity of the antibody used. For example, since the 2.5th percentile is at least similar 317 between the assays, the broadening of the interval for the IMMULITE assay is probably not 318 related to the calibrator, but to relatively higher measurement results at the upper end:an 319 explanation could be that IMMULITE assay preferentially recognizes the high free IGF-I at 320
high concentrations, while the other 2 assays more efficiently remove the impact of BPs. 321
This could have important implications in patients with disorders affecting their IGFBP 322 profile, such as acromegaly and chronic kidney disease. If confirmed in further studies, this 323 implies that a given individual must be monitored with the same IGF-I assay. 324
Another limitation of our study is that it lies on a single measurement of IGF-I while it is well 325 known that there is some within-subject variability when an individual is sampled on different 326 days (32, 33) . 327
What refinements may be expected in the measurement of this very demanding 328 analyte? The LC-MSMS method may prove to be a valid alternative and is now being used to 329 assess inter-laboratory agreement on IGF-I concentrations (34) or for validation of IGF-I 330 measures (35). Reference intervals for IGF-I provided with this LC-MS (36) seem very 331 comparable with those obtained with immunoassays. When compared with our data, lower 332 limit of normal range is similar and upper limit corresponds more or less with those observed 333 with Liaison XL or IGF1 RIACT immunoaasays. However, LC-MSMS is a time-consuming 334 and complex method that requires expensive machines and high technical expertise, because 335 many variables need to be controlled for providing accurate quantitative results 336 (e.g. extraction strategies, approaches to detect and quantify IGF-I, calibration 337 protocols…)(37). Furthermore, a recent preliminary study of an LC-MS method suggested 338 that it might miss some IGF-I protein variants (pathogenic or physiological), which are 339 present in 0.6% of the population (38). Thus, despite their limitations, immunoassays will 340 continue to be widely used, at least in the near future (39). 341
In conclusion, we have established reference intervals for six commercial IGF-I 342 assays, in a study conforming to recent international recommendations. Despite being 343 obtained in the same large population of French healthy subjects, the reference intervals 344 differed somewhat from one assay to another, and agreement between assays was moderate to 345 good. Finally, concordances between the manufacturers' reference intervals and those 346 obtained in our cohort were generally poor. These findings confirm the need to establish 347 reference intervals for each commercial IGF-I assay in a large background population. Inter-348 assay concordance with respect to the classification of patients with acromegaly or GH 349 deficiency remains to be determined, and the IGF-I standard deviation scores obtained with 350 the six assays in these subjects need to be compared. showing a good overall agreement between both immunoassays, with no significant bias. 371
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